T-Cypher Bio
Oxford
About T-Cypher Bio
T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of such therapies. T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Funding stage: Seed
- Last round: Seed (Dec 2020)
- Website: tcypherbio.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/t-cypher-bio-2214185 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.